Though it may seem that some products have been around forever, you'd be surprised to learn that many were brought on the market fairly recently. Sliced bread, a kitchen staple, has been around for fewer than 100 years. More »
Twist Bioscience Corporation (Nasdaq: TWST) today reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or therapeutic treatments. Twist’s unique monoclonal antibody candidates bind with high affinity to the receptor binding domain (RBD) on the S1 spike protein on the surface of SARS-CoV-2 viral molecules. Twist has also found antibody candidates that bind with high affinity to the human ACE2 cellular receptor, the binding site of SARS-CoV-2 in the human body.
@dc_ap_ToiToi twstホスクラ妄想まとめ fav:0 view:0
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #COVID19--Twist Bioscience Corporation (Nasdaq: TWST) today reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or…
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeuti…
Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of two synthetic SARS-CoV-2 RNA Controls. Positive controls provide quality control measures for the development, verification, and validation for diagnostic tests including both next-generation sequencing (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays; determination of the limit of detection; and monitoring of day-to-day test variations.
NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Twist Bioscience Corp. (NASDAQ:TWST) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on February 6, 2020 at ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 second quarter ended March 31, 2020, following the close of market on Thursday, May 7, 2020. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com.
As of late, it has definitely been a great time to be an investor in Twist Bioscience.
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its synthetic SARS-CoV-2 RNA Controls to provide quality control for the development, verification, and ongoing validation for diagnostic tests are now included on the U.S. Food and Drug Administration (FDA) website as reference materials for SARS-CoV-2.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its fin…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and busin…
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO, will participate in the UBS Virtual Global Healthcare Conference on Tuesday, May 19 at 10:00 a.m. Eastern Time.
Digital player serves largest pharma companies seeking to accelerate R&D; process Continue reading...
SAN FRANCISCO--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-f…
Some of our favorite rising acts in music, featuring boylife, LPB Poody, Zaia, twst, and more.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D.…
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV). This initial CEPI funding will support Inovio's preclinical and clinical development through Phase 1 human testing of INO-4800, its new coronavirus vaccine matched to the outbreak strain. CEPI previously awarded Inovio a grant of up to $56 million for the development of vaccines against Lassa fever and Middle East Respiratory Syndrome (MERS), also caused by a coronavirus.
Landmine No. 1: Smaller biotech companies short on cash will face a funding crunch if the stock market stays down. How to diffuse it: Favor biotech companies that just raised cash, or have enough on hand to cover at least 18 months of cash burn, says Jefferies biotech analyst Michael Yee. Several companies were lucky enough to raise capital right before the biotech group started to fall apart on March 6.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 9:30 a.m. Eastern Time.
Twist Bioscience (TWST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
TWST earnings call for the period ending May 9, 2020.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19. In addition, Twist Biopharma, a division of Twist Bioscience, will provide custom antibody drug discovery libraries and will screen the libraries for potential antibody therapeutics that would treat patients with COVID-19.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2020, ended March 31, 2020.
Image source: The Motley Fool. Twist Bioscience Corp (NASDAQ: TWST)Q2 2020 Earnings CallMay 8, 2020, 8:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to Twist Bioscience Fiscal 2020 Second Quarter Financial Results Conference Call.
Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of Research-Use Only (RUO) target enrichment next-generation sequencing (NGS) panels for viral detection and characterization of samples from patients testing positive for SARS-CoV-2, the virus which causes COVID-19. These panels can be used for environmental monitoring and surveillance testing, while also providing insight into full sequence information to track viral evolution and strain origin.
Twist Bioscience Corporation (Nasdaq: TWST) today announced the enhanced Twist Clonal Genes product line with the expansion of preparation quantities, delivery formats, buffer options, and tube and plate options. Customers can now access larger amounts of DNA in the format suitable for their specific research needs.
@kisaragi_memory twstつぶやきまとめ❁ fav:0 view:0
Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.